Publicaciones en colaboración con investigadores/as de Sociedad Española de Reumatología (23)

2023

  1. Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)

    Ophthalmology and Therapy

  2. SER recommendations for the treatment of uveitis

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477

  3. Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055

2020

  1. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 72, Núm. 2, pp. 216-224

2019

  1. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257

2018

  1. Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis

    Reumatologia Clinica, Vol. 14, Núm. 6, pp. 320-333

2017

  1. Development of an activity disease score in patients with uveitis (UVEDAI)

    Rheumatology International, Vol. 37, Núm. 4, pp. 647-656

  2. Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort

    Arthritis Care and Research, Vol. 69, Núm. 6, pp. 938-942

  3. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus

    Seminars in Arthritis and Rheumatism, Vol. 47, Núm. 1, pp. 38-45

  4. Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 5, pp. 752-765

  5. The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: A systematic literature review

    Seminars in Arthritis and Rheumatism, Vol. 46, Núm. 5, pp. 569-583

2016

  1. Differences between familial and sporadic early spondyloarthritis: Results from the ESPERANZA cohort

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 4, pp. 575-580

  2. Multidisciplinary dermatology–rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review

    Rheumatology International, Vol. 36, Núm. 2, pp. 221-229

2014

  1. Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme

    Rheumatology (United Kingdom), Vol. 53, Núm. 2, pp. 353-360

  2. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: Data from the Spanish registry BIOBADASER 2.0

    Rheumatology International, Vol. 34, Núm. 7, pp. 953-961

  3. The emerging problem of biological treatment in migrant and travelling populations: It is time to extend guidelines for the screening of infectious diseases

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 5, pp. 794-796

  4. Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 7, pp. 1350-1355

2011

  1. A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: The Esperanza Program

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 5, pp. 827-830

  2. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas

    Reumatologia Clinica, Vol. 7, Núm. 5, pp. 284-298

  3. Documento SER de consenso sobre el uso de terapias biológicas en la espondilitis anquilosante y otras espondiloartritis, excepto la artritis psoriásica

    Reumatologia Clinica, Vol. 7, Núm. 2, pp. 113-123